Pitfalls in evaluating the impact of persistent hematuria after induction therapy on kidney prognosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis

Kidney Int. 2024 Feb;105(2):391-392. doi: 10.1016/j.kint.2023.10.029.

Authors

Tomoki Taniguchi¹, Ryosuke Hiwa², Akio Morinobu²

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan. Electronic address: t.tomoki.0524@gmail.com.
² Department of Rheumatology and Clinical Immunology, Kyoto University, Kyoto, Japan.

PMID: 38245220
DOI: 10.1016/j.kint.2023.10.029

No abstract available

Publication types

Letter

MeSH terms

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / complications
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / diagnosis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / drug therapy
Antibodies, Antineutrophil Cytoplasmic
Hematuria / etiology
Humans
Induction Chemotherapy
Kidney
Prognosis
Vasculitis*

Substances

Antibodies, Antineutrophil Cytoplasmic